Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer

August 28, 2018

Management of HR-Sensitive, HER2-Negative Advanced Breast Cancer
The treatment paradigm for patients with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer has advanced to include addition of novel targeted therapies to endocrine agents.  With approval of novel agents and novel combinations, the treatment options for this group of patients is rapidly expanding, making the decision-making process of choosing optimal first-and subsequent line therapies quite challenging. The new combination therapies have their own safety and tolerability profile.  In order to facilitate successful integration of these advances into clinical practice and improve patient outcomes, it is important for clinicians to review the selection criteria for optimal therapy and understand the management of the associated toxicities.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Select optimal first-line therapy for patients with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer using evidence-based data and patient characteristics.
  • Devise a rational approach for sequencing second- and subsequent-lines of treatment for patients with advanced-stage HR–positive, HER2-negative advanced breast cancer.
  • Analyze efficacy and tolerability of available therapies and effectively counsel patients.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Bayer U.S. LLC
  • Celgene Corporation
  • Clovis Oncology
  • Eisai
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • Taiho Oncology

This activity is supported by an independent educational grant from TESARO.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
07/05/2018
Course expires: 
10/21/2018
Event starts: 
08/28/2018 - 1:30pm
Event ends: 
08/28/2018 - 2:30pm
Cost:
$0.00
Parent activity set: 

Melinda Telli, MD
Stanford Cancer Institute

Jessica Foran, NP
Stanford Cancer Institute

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: TBD

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
07/05/2018
Course expires: 
10/21/2018

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this upcoming live webinar.

This webinar will be presented live one time only on Tuesday, August 28, 2018, from 1:30 - 2:30 PM Eastern Daylight Time (EDT) (UTC -4).  To convert the start time of this webinar for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing